
Boehringer and Epizyme enter US$300m deal
According to BI, more than half of cancers can stem from functional errors in epigenetic modification, which diagnostically characterise the patient...

Arvelle Therapeutics raises $180m in Series A financing
It's one of the largest Series A financings for a European biotech company. A global syndicate of investors led by LSP and including...

Forbion leads €40m financing in Inflazome Ltd
Inflazome said it will use the proceeds to develop its small molecule NLRP3 inflammasome inhibitor to clinical proof-of-concept in several chronic...

New target for lung fibrosis discovered
Seeking for the reason why myofibroblasts, which normally secrete collagen in response to inflammatory signals to repair tissue injury in the lungs,...

Tissue specific tumour transition needs few cells
Anja Voss-Böhme from University Dresden and researchers at the German Cancer Center in Heidelberg used a model that links epigenetic and genetic...

Ose Pharma gets clinical milestone for IL7R antagonist
Under the deal inked in 2016, immuno-oncology and autoimmune specialist Ose Immunotherapeutics develops its IL-7-receptor...

Epigenetic drugs can increase tumour malignancy
In Nature Cell Biology the team headed by Salvador Aznar Benitah and Fran Supek reported that genetic inactivation of histone H3...